This content is from: Corporate

White list concerns exacerbated by cov-lite growth

Opposition to white lists is growing as the rise of cov-lite deals exposes investors further to the practice. But the feature is expected to linger until deal volumes start outweighing demand

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an IFLR subscriber? Login here

Instant access to all of our content. Membership Options | 30 Day Trial